David Giljohann,
CEO
Dr. Giljohann has served as CEO of Exicure since 2013. Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin where he developed oligonucleotide-modified nanoparticles, including Spherical Nucleic Acid (SNA) constructs. Dr. Giljohann has contributed to over 25 manuscripts and over 100 patents and applications. Dr. Giljohann obtained his Ph.D. in 2009 from Northwestern University.
|
|
|
